SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing heavy volume and a surge in bullish sentiment following an earnings report that highlighted improved profit margins and a strong pipeline for its AI infrastructure, leading many in the community to anticipate a significant price re-rating. While retail investors are aggressively debating the potential for a short squeeze and long-term valuation recovery, others remain cautious due to ongoing regulatory scrutiny and historical volatility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is capturing market attention as the community rallies behind its pivot from smartphones to a software-driven cybersecurity and physical AI company, bolstered by a significant Wall Street Journal spotlight and a high-profile presence at upcoming robotics expos. Investors are actively discussing the stock's potential for a major revaluation, citing robust institutional volume, a massive backlog in automotive and robotics technology, and the potential for a sustained breakout above its recent trading range.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors gear up for the imminent close of its Northern Data acquisition, a move widely viewed as a catalyst that could unlock significant AI and cloud computing potential. The community is heavily focused on the stock's record-high short interest and strong backing from Tether, leading to intense debates over the potential for a major short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant community buzz as investors anticipate potential global partnership announcements and updates regarding its AI-driven immunotherapy manufacturing technology. The discussion is heavily centered on a potential short squeeze, with retail traders pointing to high short interest and limited float as key drivers for a potential sharp upward move.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is trending as investors debate whether the company's recent earnings beat and strategic partnership with Disney signal a long-term turnaround or further decline. Community discussion is heavily divided, with some betting on a potential short squeeze fueled by high short interest and institutional interest, while others express frustration over past stock performance and skepticism regarding management's profitability targets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as market sentiment turns bullish, driven by expectations of a blockbuster year for Briumvi, strong commercial execution, and anticipation of upcoming trial readouts for subcutaneous formulations and Azer-cel. The community is actively discussing the potential for a strategic buyout and observing significant institutional accumulation, which many believe is positioning the stock for a breakout beyond current resistance levels.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors digest a positive earnings report showing significant revenue beats and reduced operating costs while keeping a close eye on the expanding Matrix-M platform, which is currently being explored for over 30 infectious disease and oncology applications. The community is actively debating the potential for future partnerships with global pharma giants and closely tracking activist investor pressure to optimize capital allocation and management structure.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently trending after an official determination from NOAA declared its deep-seabed mining application fully compliant, a key regulatory milestone that clarifies the path toward commercial recovery permits. The investment community is actively debating the significance of this development for long-term production timelines and the company's role in the critical minerals supply chain, while some investors monitor potential volatility associated with institutional selling and expiring options.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after announcing a strategic manufacturing partnership with Cellipont Bioservices to advance its ERNA-101 ovarian cancer cell therapy toward clinical trials. Community sentiment is highly polarized, with retail traders focusing on the stock's low float and short-squeeze potential, while critics remain skeptical, highlighting the company's history of reverse splits and dilution.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant volatility and intense community debate as investors navigate a disconnect between its strong product demand and a persistent slide toward 52-week lows ahead of upcoming earnings. Market participants are actively discussing institutional manipulation, potential channel stuffing concerns, and the competitive impact of private-label energy drinks, while bulls continue to position for a post-earnings recovery fueled by the company's growth narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?

ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT

M&T Bank Corp purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and...

Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy

Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss...

Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC

Cwm LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,536 shares of the biotechnology company's stock after purchasing...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-eight research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a sell recommendation, thirteen have assign...

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

Sarepta Therapeutics Inc

SRPT  Earnings Call

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits

Stocktwits Polls

Traders are closely watching the upcoming earnings report and conference call for news on guidance and pipeline progress.

Bulls are citing the high 30% short float and current market volatility as triggers for a potential short-term rally.

Investors are speculating on potential acquisition interest in the $45-$70 price range given the company's DMD franchise control.

Concerns remain regarding FDA leadership changes and the efficacy of current treatments following recent industry commentary.

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest SRPT News

SRPTSarepta Therapeutics Inc